Neogenomics (NEO) Receivables (2010 - 2026)

Neogenomics has reported Receivables for 17 years, with the latest figure at $167.4 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 10.72% year-over-year to $167.4 million; the trailing twelve-month figure through Mar 2026 stood at $167.4 million (up 10.72% YoY), and the FY2025 full-year result was $159.2 million, up 5.71% from the prior year.
• Receivables for Q1 2026 stood at $167.4 million, up from $159.2 million in the prior quarter.
• The five-year high for Receivables was $167.4 million in Q1 2026, with the low at $112.4 million in Q1 2022.
• Historically, Receivables has averaged $138.1 million across 5 years, with a median of $140.5 million in 2024.
• Annual changes were most pronounced in 2024 — Receivables rose 17.13% — and 2025, when it increased 2.55%.
• Neogenomics' Receivables stood at $121.6 million in 2022, then gained by 7.94% to $131.3 million in 2023, then grew by 14.76% to $150.6 million in 2024, then climbed by 5.71% to $159.2 million in 2025, then advanced by 5.14% to $167.4 million in 2026.
• The last three Receivables figures came in at $167.4 million (Q1 2026), $159.2 million (Q4 2025), and $155.3 million (Q3 2025), per Business Quant data.